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IMMUNOTHERAPEUTIC OPTIONS FOR THE TREATMENT OF 
NEUROBLASTOMA: AN ANALYSIS OF NATURAL KILLER CELL AND 
GAMMA DELTA T CELL BASED IMMUNOTHERAPY 
CATHERINE E BIXBY 
ABSTRACT 
Neuroblastoma is an aggressive solid tumor that develops from immature cells of the 
nervous system and is almost exclusively diagnosed in infants and young children.  
Over the past decade a multitude of immune based therapies have been explored as 
therapeutic candidates for patients with neuroblastoma. The anti-GD2 monoclonal 
antibody, 3F8, and more recently, natural kill (NK) cell based therapies have been 
accepted as hopeful therapeutic options for patients with Neuroblastoma. These options 
however have many drawbacks including dose limiting pain, the development of 
tolerance, reliance on MHC mismatch and possible reliance on the invariant NK (iNK) 
cells population.  
γδ T cells, a subpopulation of T cells composed of a T cell receptor (TCR) with a 
γ and a δ chain instead of an α and a β chain, have been shown to recruit a more robust 
immune response then both 3F8 and NK cells through their activation of antigen 
presenting cells (APCs) and non-reliance on MHC mismatch. γδ T cells are also able to 
recruit NK cells as well as other cytotoxic lymphocytes. For these reasons, it is believed 
that γδ T cell based treatment alone or in combination with an anti-GD2 monoclonal 
antibody may have a greater efficacy than either NK cells or an anti-GD2 monoclonal 
antibody alone. The intent of this thesis is to explore and evaluate the current state of γδ 
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T cell based immunotherapy against the backdrop of NK cell based immunotherapy for 
neuroblastoma. 
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Introduction 
 
Neuroblastoma is an extra cranial solid tumor that develops from nervous tissues 
forming the sympathetic nervous system. The majority of neuroblastoma develop in the 
adrenal gland, with the remainder developing in other sites related to sympathetic 
nervous tissues1. Neuroblastoma makes up 8-10% of all childhood cancers and 15% of all 
cancer deaths in children with 50% occurring before the age of 2 years and 10.5 per 
million in children less than 15 years of age1. Neuroblastoma is more commonly seen in 
the United States and Europe than in other countries1,2 .  
Immunotherapy and Neuroblastoma 
The intent of this thesis is to explore and evaluate the current state of gamma delta 
(γδ) T cell based immunotherapy against the backdrop of natural killer (NK) cell based 
immunotherapy for neuroblastoma. The idea that immunotherapy could be used in the 
treatment of cancer arose from Dr. Coley’s observation in 1890 that following the 
contraction of acute bacterial infections patient’s tumors spontaneously regressed 3 . 
Following Dr. Coley’s observation, an increased prevalence of tumors in patients with 
either congenital or acquired cellular immunodeficiency syndromes was reported 3. The 
prospect of using immunotherapy to treat cancer is attractive due to the specificity and 
memory of the immune system enabling a longer more sustained treatment response with 
reduced toxicity 3. The use of immunotherapy to treat neuroblastoma is particularly 
attractive since neuroblastoma is a disease of infants, children, and adolescents; 
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populations especially sensitive to the devastating long term side effects and toxicity of 
traditional chemotherapy treatments 3.  
Both NK cells and γδ T cells are being investigated as immunotherapeutic options 
for neuroblastoma. Currently, NK cell based therapy is more widely accepted, though 
there are many drawbacks. These include the reliance on major histocompatibility 
complex (MHC) mismatch and possible reliance on invariant NK (iNK) cells. 
Additionally, NK cells cannot produce memory cells and have a lower efficacy then γδ T 
cells. 
 γδ T cells have been shown to recruit a wide immune response through activation 
of antigen presenting cells (APCs) and are not reliant on MHC mismatch. γδ T cells 
additionally recruit NK cells and other cytotoxic lymphocytes. For these reasons, it is 
believed that treatment with γδ T cells can have a greater efficacy than that with NK 
cells. 
Demographics  
It was noted in a study by the Children’s Oncology Group (COG) on 3539 neuroblastoma 
patients from the United States that neuroblastoma was more common in Caucasian then 
in Black infants however this difference disappeared in older children 4. Despite the 
lower prevalence of neuroblastoma among Black infants the COG observed that a 
significantly higher proportion of patients with high-risk disease existed among black 
infants then between Caucasian, Hispanic, or Asian infants 4. Furthermore black children 
and adolescents of all ages showed a significantly worse 5 year event free survival rate 
and more aggressive disease 4. COG proposed that these differences arose from genetic 
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factors, specifically polymorphisms affecting the metabolism of common 
chemotherapeutic agents used in neuroblastoma treatment regimens, which would leave 
black patients more resistant to chemotherapy and at an increased risk of developing 
toxicities from chemotherapy 4. Differences in disease presentation and course in this 
ethnic and racial group were not attributed to differences in healthcare accessibility since 
the COG group’s data did not show that tumor stage advanced with time and the status of 
tumor biomarkers remained stable 4. The highest mortality rate is seen in patients 
between the ages of 17 and 18 months: 36.4% of Stage 4S and 67.1% of Stage 4 1. Given 
the low survival rates of advanced neuroblastoma, an effective therapy is needed to treat 
these patients. The demographics of the patient population primarily affected by 
neuroblastoma warrants that alternative forms of therapy be explored to avoid the long 
term devastating side effects from tradition therapies.  
Unfortunately there are many challenges, including large tumor bulk in both the 
primary tumor and metastases and rapid proliferation capable of overwhelming a child’s 
under developed immune system that make the delivery of effective immunotherapy 
challenging 5.  Additionally the limited number of unique surface epitopes on 
neuroblastoma cells and a powerful immunosuppressive microenvironment created by the 
tumor makes T cell based immunotherapy exceedingly difficult 5.  Neuroblastoma tumors 
frequently manipulate the expression of MHC proteins on their surface in order to evade 
T cell attack and resist NK cell mediated antibody dependent cell cytotoxicity (ADCC) 5. 
Neuroblastoma tumors also regularly release proteins capable of inhibiting both T and 
NK cells and recruit macrophages capable of disabling lymphocytes 5. Although there are 
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many challenges in delivering immunotherapy to neuroblastoma tumors, the observation 
that a significant number of stage 4S tumors, seen exclusively in infants, spontaneously 
regress suggests that de novo anti-tumor immunity may occur in some patients.  
Classification 
In 2009, the International Neuroblastoma Risk Group (INRG) Project proposed a new 
staging system that focused more on radiological findings rather than surgicopathological 
findings (Table 1). Table 1 summarizes the previous and current classification systems.  
Table 1: Comparison of original and new classification schemes4 
 
Description of Original INSS Tumor Stages Descriptions of New INRG Tumor 
Stages 
Tumor 
Stage 
Description Tumor Stage Description 
1 Localized tumor with complete gross excision, with or 
without microscopic residual disease; representative 
ipsilateral lymph nodes negative for tumor 
microscopically. Nodes attached to and removed with 
the primary tumor may be positive. 
L1 Localized 
tumor not 
involving vital 
structures, as 
defined by the 
list of image 
defined risk 
factors (IDRFs), 
and confined to 
one body 
compartment 
2A Localized tumor with incomplete gross excision; 
representative ipsilateral nonadherant lymph nodes 
negative for tumor microscopically 
L2 Local-regional 
tumor with 
presence of one 
or more IDRFs 
2B Localized tumor with or without complete gross 
excision; representative ipsilateral nonadherant lymph 
nodes positive for tumor; enlarged contralateral lymph 
nodes negative microscopically 
  
3 Unresectable unilateral tumor infiltrating across the 
midline (beyond the opposite side of the vertebral 
column) with or without regional lymph node 
involvement, or midline tumor with bilateral extension 
via infiltration (unresectable) or lymph node 
involvement 
  
4 Any primary tumor with dissemination to distant lymph 
nodes, bone, bone marrow, liver, skin, and/or other 
organs (except as defined for stage 4S disease) 
M Distant 
metastatic 
disease (except 
stage MS 
  5 
tumor) 
4S Localized primary tumor (as defined for stage 1, 2A, or 
2B disease) with dissemination limited to skin, liver, 
and/or bone marrow (limited to infants younger than 1 
year, marrow involvement of less 10% of total 
nucleated cells, and Iodine-123 
metaiodabenzylguanidine (MIBG) scan findings 
negative in the marrow) 
MS Metastatic 
disease in 
children 
younger than 18 
months, with 
metastases 
confined to 
skin, liver, 
and/or bone 
marrow 
 
  
Signs, Symptoms, Differential Diagnosis 
 
The most common clinical presentation of neuroblastoma is abdominal distention 
corresponding to the most common tumor site, the adrenal medulla 6. The abdominal 
mass causes swelling which may led to abdominal pain and/or a feeling of fullness 
driving the patient to not eat and resulting in marked weight loss 6. Since neuroblastoma 
tumors commonly sit on the adrenal medulla they frequently cause an increase in 
catecholamine secretion 1,6. The increased concentration of catecholamines specifically, 
epinephrine, norepinephrine, and dopamine result in various symptoms associated with 
hyper-vigilance such as increased blood pressure, tachycardia, significant perspiration, 
reddening of the skin, and fever 6. In addition to catecholamines, neuroblastoma tumors 
on the adrenal medulla frequently secrete vasoactive intestinal peptide (VIP). VIP relaxes 
the smooth muscle of the digestive system and simultaneously promotes the secretion of 
water and electrolytes and intestinal motility. Patients with neuroblastoma therefore also 
frequently present with watery diarrhea 3. Other common morbidities seen in patients 
with neuroblastoma are Horner’s syndrome, a syndrome comprised of multiple 
conditions including a drooping eyelid, pupil constriction, enophthalmos, and anhidrosis 
all relating to a disturbance of the sympathetic nervous system 7, and various 
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paraneoplastic syndromes such as opsoclonus myoclonus syndrome characterized by 
rapid conjugate eye movements and involuntary muscle twitching6. Differential 
diagnoses include Wilm’s tumor (in the abdomen), lymphoma (in the neck), and Ewing’s 
sarcoma and lymphoma (small round cell tumor in the bone) 1.  
Current Immunotherapy Treatment Regimens for Neuroblastoma  
For reasons previously explained, research has focused on developing antibody-targeted 
cytotoxic therapies using monoclonal antibodies directed against oncofetal antigens such 
as the gangliosides; GD2, GD3 and GM2, which are commonly expressed on 
neuroblastoma tumors rather then exploring traditional T cell, - based immunotherapies 5. 
Neuroblastoma cells are ideal candidates for monoclonal antibody targeting therapy since 
they ubiquitously express high levels of the GD2 disialoganglioside, a marker restricted 
to cells of neuroectodermal origin 8,9,10,11. Further evidence supporting the use of 
monoclonal antibodies targeting the GD2 disialoganglioside on neuroblastoma cells has 
been provided by Cheung et al who observed that this antigen is not downregulated at the 
cell surface in response to monoclonal antibody treatment 11,12.  Additionally it is known 
that the GD2 oncofetal antigen is T cell independent, within close proximity of the 
neuroblastoma cell’s membrane, and expressed in high density on neuroblastoma cells 5. 
In addition to GD2, neuroblastoma cells also express the GD3 and GM2 
disialogangliosides. Other targets include CD56, a prominent marker on neuroendocrine 
tumors and an essential component for neurogenesis, neuronal migration, and neurite 
outgrowth 13, and L1-CAM, a neuronal cell adhesion molecule 8. GD2 monoclonal 
antibodies conjugated to toxins, radionucleotides, or powerful growth factors such as 
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interleukin-2 (IL-2) serve as the cornerstones of immunotherapy for neuroblastoma since 
they are capable of targeting neuroblastoma cells and recruiting effector cells to carry out 
ADCC, activating complement, and releasing inflammatory cytokines 14. GD2 
monoclonal antibody based treatment regimens are frequently used in patients with 
advanced (high-risk) neuroblastoma.  
Although anti GD2 monoclonal antibodies are a standard of care in treatment 
regimens for neuroblastoma because they are effective at targeting and killing 
neuroblastoma cells they have several limitations preventing them from being an ideal 
therapeutic option. The GD2 antigen is not exclusively expressed by neuroblastoma cells 
but is expressed by cells of neuroectodermal origin 9. Therefore other cells of 
neuroectodermal origin such as neurons and peripheral pain fibers also expressing GD2 
can be targeted by GD2 monoclonal antibodies resulting in bystander cell lysis, 
inflammation from ADCC and complement activation, as well as dose limiting pain 5,14. 
Dose limiting pain is thought to result both from the binding of anti-GD2 antibodies to 
peripheral pain fibers and from the activation of the complement system 7.  
 The effectiveness of GD2 monoclonal antibodies in treating neuroblastoma is 
additionally limited by the response of the patient’s immune system. The initial GD2 
monoclonal antibodies were first developed using the murine 3F8 antibody 14. The 
continual administration of murine 3F8 results in the patient producing human anti-
mouse antibodies (HAMA), which neutralize GD2 antibody treatment 15. Since GD2 
antibody treatments are only successful prior to production of HAMA the less 
immunogenic human-mouse chimeric anti-GD2 monoclonal antibody, ch14.18 was 
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developed 16. Although ch14.18 did not provoke the production of HAMA, it did initiate 
the formation of human anti-chimeric antibodies 16.  
Recently a humanized anti GD2 monoclonal antibody, hu14.18 has been 
developed 17. Although hu14.18 is far less immunogenic then either 3F8 or ch14.18, its 
effectiveness depends on the strength of the patient’s immune system and the ability of 
the immune system to signal a powerful effector response. Anti-GD2 monoclonal 
antibodies are not effective enough when used alone to fight Neuroblastoma and thus 
must be integrated into the third and final maintenance stage of a patient’s treatment 
protocol 6. Prior to receiving anti-GD2 monoclonal antibodies the patient must undergo 
induction chemotherapy and possibly a hematopoietic stem cell transplant (HSCT) 6. 
Cyclophosphamide, a cytotoxic drug that induces immunodeficiency, in addition to other 
cytotoxic agents, is the backbone of induction chemotherapy for Neuroblastoma. In 
addition to cyclophosphamide patients requiring a HSCT must receive myeloablative 
chemotherapy in preparation for an autologous HSCT rescue 6. The treatment patients 
receive prior to the administration of anti-GD2 monoclonal antibodies is chemotoxic to 
all elements within the bone marrow including immune-competent white blood cells 6. 
Patient’s immune systems are suppressed not only by numerous drugs used in the first 
two stages: induction and consolidation (HSCT) of treatment, but also by the stress 
imposed by various supportive measures that leave patients highly susceptible to 
infections: intravascular catheters, ports, prolonged hospital stays, multiple intravascular 
procedures, and mucosal lesions arising from induction chemotherapy 6. Since patients 
with neuroblastoma are immunocompromised the strength and effectiveness of anti-GD2 
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monoclonal antibody treatment is reduced 14. This may explain why a study conducted by 
Shusterman et al. and the Children’s Oncology Group found that hu14.18 treatment only 
provided bone marrow remission in patients with minimal disease 14. In order to activate 
leukocytes in immune-compromised patients to carry out a powerful ADCC killing attack 
of neuroblastoma cells upon anti-GD2 antibody infusion, anti-GD2 antibodies have been 
combined with interleukin-2 (IL-2) 5. IL-2 stimulates T cells, NK cells, and NK T cells 
thus producing a more robust immune response against neuroblastoma tumors in 
immune-compromised patients. However in several studies, most notably Shusterman et 
al. and Yu et al., infusion of IL-2 resulted in grade 3 or 4 capillary leak and abnormal 
liver function tests 14,18. The immunocomprised state of the patient and dose limiting pain 
from anti-GD2 monoclonal antibody based treatments remain significant barriers 
hindering this therapy’s efficacy and potential 5,14. 
It is possible however for anti-GD2 monoclonal antibodies administered in 
conjunction with either NK or γδ T cells to mount an attack strong enough to eliminate 
the need for induction chemotherapy. In a study conducted by Tarek et al. the effect of 
administering the anti-GD2 monoclonal antibody, 3F8, in conjunction with either NK 
cells or chemotherapy was measured 19. Tarek et al. found that patients who received NK 
cells following 3F8 administration lived on average 32-68 months longer then patients 
receiving chemotherapy and 3F8 (50 – 114 months verses 18 – 51 months) 19. The 
prolonged survival period of patients receiving NK cells following treatment with 3F8 
was attributed to the removal of chemotherapy from the treatment protocol, which 
reduced the degree of immunosuppression and made it easier for the patient’s immune 
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system to launch a powerful effector response against neuroblastoma cells. NK cells 
exhibit a redundant activation pattern when administered with anti-GD2 monoclonal 
antibodies thus enabling NK cells, along with 3F8, to launch an effector response strong 
enough to eliminate the need for induction chemotherapy. NK cells are activated by the 
3F8 antibody through the CD16 marker expressed on their surface and by neuroblastoma 
cells through their natural cytotoxicity receptors: NKp30, NKp44, NKp46, and the 
DNAX accessory molecule-1 (DNAM-1) adhesion receptor 19. 
Background of Natural Killer Cells 
NK cells are lymphoid cells vital to the innate immune response and involved in the 
adaptor immune response. They are actively involved in the destruction of virally 
infected and malignant cells. Similar to B-lymphocytes, T lymphocytes, and dendritic 
cells, they arise from the Common Lymphoid Precursor in the bone marrow 12. They then 
settle in hematopoietic tissue and peripheral organs lacking B and T lymphocyte 
markings 12. The NK cell population is defined by the absence of the CD3 marker and 
presence of either/or the CD56 or CD16 marker 20. The five known populations of NK 
cells are: CD56dimCD16bright, CD56brightCD16dim, CD56brightCD16-, CD56dimCD16-, and 
CD56-CD16bright 20. The presence or absence of the CD16 marker on the NK cell surface 
serves as an indication of the NK cell’s principle function. CD16dim or CD16- NK cells 
typically express the lectin based activating receptors, NKG2A/CD94 and 
NKG2C/CD94, instead of the CD16 marker or the killer immunoglobulin receptors 
(KIRs) 20. The lectin based activating receptors bind to HLA-E molecules triggering an 
innate immune response 20. Binding of NKG2A/CD94 and NKG2C/CD94 to HLA-E 
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molecules additionally enables NK cells to monitor the expression levels of other HLA 
molecules whose expression levels serve as indicators of disease 20. The CD16dim and 
CD16- NK cells also express the chemokine receptors CCR7, involved in B and T 
lymphocyte activation, and CXCR3, involved in Th1 cell migration to the cytoskeleton 
and the activation of integrin 20. CD16bright NK cells are involved in ADCC, express 
KIRs, and migrate to sites of inflammation 20. The CD16dim and CD16- NK cells, 
involved primarily in immune regulation, reside in the tonsils and lymph nodes while the 
CD16bright NK cells reside principally in the peripheral blood and spleen 20. 
 In order for immature NK cell precursors in the bone marrow to mature into fully 
functional NK cells only the cytokine, interleukin-15 (IL-15) must be present 12. Unlike B 
and T lymphocytes, NK cell maturation does not require the recombination of genes 
encoding immunoglobulins or the T cell receptor 12.  NK cells additionally differ from B 
and T lymphocytes in that they do not require previous antigen exposure or antigen 
presentation through the MHC to recognize and attack infectious cells 12. NK cells are 
instead activated or inhibited through their surface activating and inhibiting receptors that 
respond to a variety of ligands and chemical signals. The presence of activating ligands 
and chemical signals on a tumor cell’s surface fluctuates depending on the state of the 
tumor cell’s environment and degree of DNA damage 21. Significant DNA damage and a 
stressful microenvironment can cause a tumor cell to upregulate NK receptor ligands 
leading to the increased activation of NK cells bearing the corresponding activating 
receptors 21. NK cells respond to activating signals by either releasing cytoplasmic 
granules of perforin and granzyme, expressing Fas-ligand (Fas-L) or TNF-related 
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apoptosis inducing ligand (TRAIL) to induced death receptor mediated apoptosis, 
carrying out ADCC through their CD16 surface marker, or producing large quantities of 
cytokines, most notably, interferon-γ (IFN-	  γ), tumor necrosis factor-α (TNF-α), 
interleukin-8 (IL-8), and interleukin-10 (IL-10) [2^](23) 21. IFN-γ activates CD8+ T cells, 
initiating their transformation into cytotoxic (CTL) T cells and slows tumor growth 
through signaling to angiostatic chemokines 21. IL-8 attracts neutrophils and IL-10 
enhances the survival, proliferation, and antibody production of B lymphocytes 21. NK 
cells are also capable of secreting cytokines necessary for the growth and development of 
specific hematopoietic cell lineages such as, granulocyte-macrophage colony stimulating 
factor (GM-CSF) 22. Thus NK cell activation and cytokine secretion results in the 
development and activation of CTL T cells along with other immune effector cells for a 
potent immune response.  
 Since NK cells carry both activating and inhibiting receptors on their surface they 
are able to activate and enhance as well as dampen the immune system. The KIR family 
represents the largest family of activating and inhibiting receptors on NK cells 22. The 
genes, located on the long arm of chromosome 19 (19q13.4) within the leukocyte 
receptor complex (LRC), controlling expression of KIRs on NK cells are highly 
polymorphic at both the haplotype and allelic level 22. Inhibiting and activating KIR 
receptors, although structurally similar on their extracellular surface, differ structurally on 
their cytoplasmic surface 22. On the cytoplasmic surface both activating and inhibiting 
receptors contain immunoreceptor tyrosine based motifs 22. Upon ligand recognition, the 
inhibitory motif on the inhibiting KIR receptors associates with SHP-1, SHP-2, and SHP 
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phosphatases leading to the inhibition of phosphorylation and blockage of the cellular 
cascade necessary for NK cell activation 12. The immunoreceptor tyrosine based motif on 
activating KIR receptors instead associates with the transmembrane adaptor protein, 
DAP10 upon ligand recognition, which results in activation of the P13 kinase pathway 
leading to the activation of NK cells 22. The activation of NK cells results in perforin and 
granzyme mediated cell lysis 22.  
 The KIR inhibiting receptors on NK cells recognize and respond to MHC I, which 
is expressed constituently on the surface of healthy cells 23. Since the genes responsible 
for encoding the NK cell’s KIR inhibiting receptors are located on chromosome 19 and 
segregate independently from the genes encoding MHC I on chromosome 6, it is possible 
for an individual to express an inhibiting KIR receptor but not the receptor’s 
complementary ligand 24. The probability of this occurring is increased given that the 
decision of which encoded inhibiting KIRs to express is random 24. It is also possible for 
an individual NK cell to express multiple different inhibiting KIR subtypes each with 
different ligand specificities 24.  
 The NKG2D receptor is the primary activating receptor expressed by all NK cells 
and the majority of γδ and CD8+ T cells 25.  The ligands for the NKG2D receptor are 
either of MHC I homology (MICA, MICB, and ULBP-4) or glycophosphatidylinositol 
anchored proteins (ULBP-1, ULBP-2, and ULBP-3) 25.  In contrast to ligands for the 
inhibiting KIRs, the NKG2D receptor ligands are expressed almost exclusively on 
unhealthy cells and have been found on a variety of carcinomas including (but not limited 
to): breast, lung, ovary, brain, and kidney 25.  
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 The ability of NK cells to elicit an effector response against a target cell is 
dependent on the licensing status of the NK cell. Although the exact time point and 
location of NK licensing remains unknown, it is understood that NK cell licensing has a 
significant protective function by ensuring that only NK cells capable of distinguishing 
self from non-self MHC ligands are able to provoke an effector response 26. If an NK 
cell’s inhibiting KIR is unable to recognize and interact with self-MHC ligands then the 
cell is unlicensed and thus inert 26. Only after the NK cell’s inhibiting KIR engages with a 
self-MHC ligand can its activating receptor respond to incoming stimuli by producing 
and releasing INF-γ, TNF-α, IL-8, IL-10, perforin and granzyme 26.  The number of self-
MHC ligands the NK cell’s inhibiting KIR can engage with is positively correlated with 
the strength of the effector response elicited by the NK cell 26. Given that an individual’s 
NK cells express different inhibiting KIR, different NK cells will require different MHC 
ligands for licensing yielding a population of both licensed and unlicensed NK cells in an 
individual. In addition to the ability to recognize and engage with self-MHC ligands, a 
NK cell’s inhibiting KIR receptor must also have an intact immunoreceptor tyrosine 
inhibitory motif 26.  
Since NK cells carry both inhibiting and activating receptors on their surface, 
their response to different target cells depends upon the integration of inhibitory and 
activating signals from that cell 22. The target cell has the ability to either upregulate or 
downregulate its’ expression of inhibitory or activator ligands and this affects the NK 
cells’ response 22.   
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The immunotherapeutic potential of NK cells lies in the highly polymorphic 
nature of their inhibiting KIR, which allow them to detect abnormal cells via the “missing 
self” hypothesis in HSCT and evoke a powerful graft verse leukemia effect (GVL) 27. 
The “missing self” hypothesis was first observed by Ruggeri et al who demonstrated that 
the NK cell activation threshold is lowered upon the infusion of donor licensed NK cells 
into a recipient lacking at least one of the MHC class I ligands for the donor’s NK KIR 27. 
The reduced NK activation threshold in this patient led to a significantly more powerful 
NK cell mediated immune response 27. Several qualities of NK cells such as their short 
survival period, limited expansion abilities, and inability to form memory cells make 
them attractive candidates for immune based therapies, by allowing repeated dosing and 
the ability to design more patient specific therapies 28. These qualities however also limit 
the potency of an NK cell attack. Although the therapeutic use of activated NK cells to 
treat solid tumors has shown promise there are challenges, discussed further below, 
which limit their use for neuroblastoma.  
γδ T cells 
γδ T cells are a heterogeneous population differing structurally from αβ T cells in their T-
cell receptor (TCR) element. The majority of T cells are αβ T cells with γδ T cells 
making up only 10% of the T-cell population 16. Of this 10%, 1-5% are peripheral γδ T 
cells residing within the circulation 16. The remaining γδ T cells are scattered throughout 
the liver, dermis, spleen, lymph nodes, and reproductive tract 29. 
The TCR of both αβ and γδ T cells exists as a heterodimer 30. The α-chain gene 
locus for the αβ T cell’s variable chain within the TCR contains both “V” and “J” genes 
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while the β-chain gene locus contains “V”, “D”, and “J” genes 30. Upon activation of VDJ 
recombinase, the β-chain gene locus undergoes VDJ recombination and the α-chain gene 
locus undergoes VJ recombination 30. These two recombination events yield a T cell 
population with highly diverse TCRs 30. Each αβ T cell TCR is unique to one particular 
MHC complex 30. This high level of diversity enables the recognition of a wide range of 
MHC molecules.  
γδ T cells differ from the more prevalent αβ T cells in that their TCR is composed 
of a γ chain and a δ chain 8,15,30,. The γ chain is located on a separate gene locus from the 
α-chain and β-chain gene loci and contains the “V” and “J” gene segments 30. The gene 
locus of the δ chain, on the other hand, is located within the α chain gene locus and 
contains the “V”, “D”, and “J” gene segments 30. Although the two populations have 
different TCRs, both α: β and γ: δ T cells express the CD3 antigen 30.  
The development of γδ T-cells in the thymus is significantly different then αβ T 
cell development 30. αβ T cells require the thymus for proper development and are 
subjected to three stages of selection: β-selection, positive selection, and negative 
selection 8,30. γδ T cells, on the other hand, are capable of developing without the thymus 
as indicated by various studies demonstrating that patients with DiGeorges Syndrome, 
which results, in thymic hypoplasia, develop fully functional γδ T cells but no αβ T cells 
31. Key differences in αβ T cell and γδ T cell development occur during β-selection in the 
thymus 30. During β-selection assembly of the pre-TCR commits intrathymic precursors 
to the αβ T cell lineage 8,30. These cells will subsequently undergo positive and negative 
selection before leaving the thymus 8,30. γδ T cells do not undergo β-selection but instead 
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express a γδ TCR instead of a pre-TCR 30. Although its widely believed that the decision 
to express a pre-TCR or γδ TCR designates whether an intrathymic precursor develops 
into an αβ or γδ T cell; there is some evidence that suggests high expression levels of the 
interleukin-7 (IL-7) receptor, independent of the expressed TCR, determines whether a 
precursor develops into a γδ T cell 30. γδ T cells, as opposed to αβ T cells, exhibit high 
expression levels of the IL-7 receptor 30. 
γδ T cells are categorized based on the identity of their γ and δ variable chains 
29,30. It remains unknown whether the γ and δ variable chain subtypes are determined 
randomly in the initial development of the γδ TCR or whether the subtypes are 
intentionally chosen based on the intended tissue location or function of the future γδ T 
cell 29,30. Two significant populations of γδ T cells are the Vγ9+Vδ2+ γδ cells and the 
Vγ2+Vδ2+ γδ cells 29,30. The majority of peripheral γδ T cells, capable of comprising up to 
98% of the total circulating γδ T cell population, are Vγ9+Vδ2+ cells 30. Although the 
Vγ9+Vδ2+ population is more prevalent, it is the Vγ2+Vδ2+ population that is believed to 
be most important for cellular immunity 30. Upon microbial infection the Vγ2+Vδ2+ 
population expands from composing only 0.5%-5% of the peripheral γδ cell population to 
composing 50% of both αβ and γδ circulating T cells 30. The immediate expansion upon 
microbial infection of the Vγ2+Vδ2+ population supports the belief that γδ T cells are 
heavily involved in cellular immunity and react to infections at a much earlier stage then 
αβ T cells 30. Unlike αβ T cells, γδ T cells are widely believed to be members of both the 
innate and adaptive immune system 30.  
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In order for αβ T cells to become activated and evoke an effector response, 
antigenic peptides must be presented by either MHC I or MHC II complexes located on 
the cellular surface 16. γ: δ T cells are unique T cells in that they do not require MHC 
presentation of antigenic peptides for activation or to evoke an effector response 8,30. 
Furthermore, it is unnecessary for them to express either the CD4 or CD8 marker 8,30. 
Although γδ T cells do not need to express either the CD4 or CD8 marker, these markers 
can be found on small subsets within the γδ T cell population. The CD8 marker has been 
found on γδ T cells following cytomegalovirus (CMV) infection, in patients with human 
immunodeficiency virus (HIV), and in renal transplant recipients 30. The majority of γδ T 
cells expressing the CD8 marker reside within the gut and are identified as Vγ5+Vδ4+ 30. 
A very small population of γδ T cells carries the CD4 marker 30. This population is 
known to secrete increased amounts of Th1 cytokines including, IFN-γ and GMCSF 30. 
The population is also known to illicit antibody production and produce Th2 cytokines 
such as interleukin-4 (IL-4) 30.  
It is widely believed that γδ T cells are by default Th1-like cells while CD4+ αβ T 
cells differentiate into either Th1 or Th2 cells 30,32. Despite this, its been observed that a 
small subset of CD4+ γδ T cells can become Th2-like cells and it is known that the 
presence of various pathogens and cytokines can influence whether a γδ T cell 
differentiates into a Th1-like or Th2-like cell 30. Yin et al. observed that γδ T cells, even 
when exposed to the Th2 development transcription factor, GATA3, in addition to IL-4 
and IFN-γ, differentiate into Th1-like cells and secrete interleukin-12 β2 (IL-12 β2) 33. 
Yin et al. demonstrated that the majority of γδ T cells are destined to become Th1-like 
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cells and are thus heavily involved in the primary immune response. From Yin et al.’s 
observations it can be deduced that γδ T cells play a role in tumor immunology since 
Th1/Th1-like cells are more important then Th2/Th2-like cells for an antitumor immune 
response 32. Although both Th1/Th1-like and Th2/Th2-like cells can eradicate tumors, 
Th1/Th1-like cells directly attack tumor cells through the secretion of IFN-γ and 
generation of CTLs while Th2/Th2-like cells indirectly attack tumor cells by inducing 
inflammation occasionally leading to necrosis 32. The Th1/Th1-like cell mediated attack is 
additionally superior because it confers immunological memory and results in the 
secretion of perforin, TNF-α, and Fas/FasL, all highly cytotoxic agents 32. Th1/Th1-like 
cells additionally have strong adhesion properties through their upregulation of leukocyte 
functional association antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-
1) 32.   
Although Th2 /Th2-like cells can kill tumor cells through promoting inflammation 
eventually leading to necrosis, they do not confer immunological memory specifically for 
CTL T cell generation and secrete large amounts of interleukin-6 (IL-6) and IL-10, both 
strongly associated with cachexia/wasting syndrome 32. Furthermore, the inflammation 
induced by the Th2/Th2-like response can promote tumor growth 34. The cytokines, 
chemokines, and eicanosoides released by Th2/Th2-like cells stimulate the proliferation 
and migration of tumor cells by promoting angiogenesis 34. By attracting numerous 
infiltrating leukocytes, the inflammatory reaction induced by Th2/Th2-like cells helps to 
remodel the extracellular matrix and thus facilitates tumor cell migration 34.  
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γδ T cells express the chemokine receptor CCR5 and secrete inflammatory 
cytokines such as IFN-γ and TNF-α, which allows them to enter infected tissues and 
respond to infection 8,16,17,35. As they mature, γδ T cells acquire characteristics of 
professional APCs. Some γδ T cells temporarily reduce their expression of inflammatory 
cytokines and instead upregulate their expression of the chemokine receptor, CCR7 
which allows them to present antigens to αβ T cells 8,16.  
Similar to NK cells, γδ T cells respond to the stress-induced MIC proteins 
expressed on the surface of cells from epithelial origins 30. The proteins MICA and MICB 
resemble MHC I proteins and act as ligands for the NKG2D receptor expressed on NK 
cells, CD8 αβ T cells, and γδ T cells 15, 30. Therefore treatment strategies seeking to 
activate NK cells through their NKG2D receptors can theoretically also activate γδ T 
cells. γδ T cells also carry the receptor, FcγR, necessary for ADCC 36. The majority of 
monoclonal antibody targeting therapies kill tumor cells by inducing ADCC 36. γδ cells 
could thus serve as a valuable adjuvant to monoclonal antibody targeting therapies 
particularly in patients with diminished NK cell activity. The ability to activate both γδ T 
cells and NK cells through one receptor is beneficial because it ensures that a backup 
population of cells will always be activated and available to evoke an anti-tumor immune 
response. 
In addition to the expression of NKG2D, the NK activating receptor, γδ T cells 
are linked to the innate immune system through their expression of toll like receptors 
(TLRs) and ability to activate other TLRs 32. The TLRs are part of the innate immune 
system and recognize pathogen-associated molecular patterns (PAMPS) and damage 
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associated molecular patterns (DAMPS) both of which are associated with tumors and 
carcinogenesis 32, 37. TLRs respond to PAMPS and DAMPS by signaling the expression 
of specific genes, through the activation of signal transduction pathways, which help 
develop antigen specific immunity 38. The recognition of PAMPS and DAMPS by TLRs 
on γδ T cells’, results in the secretion of cytotoxic antitumor cytokines by γδ T cells 30, 38. 
The presence of TLRs on γδ cells strengths their ability to recognize and react to tumors 
and supports their potential use in immune based anti-tumor therapies. 
Several qualities of γδ T cells suggest that they can generate a more powerful 
anti-tumor immune response than NK cells, dendritic cells, and αβ T cells. Although the 
NK cell’s ability to illicit a powerful anti-tumor response has been recognized and 
harnessed in NK based therapies, Meraviglia et al. and other groups have observed a 
depletion in the NK cell’s ability to attack and kill tumors following monoclonal antibody 
therapy 36. In addition, a study conducted by Maniar et al. suggests that γδ cells may even 
be able to induce the activation of NK cells and further prompt NK cells to kill NK cell 
resistant tumors 39.  
Along with the activation of NK cells, γδ T cells promote dendritic cell 
maturation through the secretion of TNF-α 30. Dendritic cells are an essential component 
to the adaptive immune response against tumors. They are able to cross present tumor 
antigens to CD8+ T cells as well as secrete interleukin-12 (IL-12), which promotes αβ T 
cell differentiation into anti-tumor Th1 cells 30, 40. Increased dendritic cell maturation 
would result in a more powerful anti-tumor attack by the immune system. γδ T cell 
activation does not require MHC presentation of antigen peptides however when 
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stimulated, γδ T cells are able to both upregulate and produce MHC II molecules de novo 
30. Dendritic cells, on the other hand when stimulated, are only able to upregulate already 
existing MHC II molecules 30. The increased presence of MHC II molecules following γδ 
T cell mediated de novo production and upregulation increases the activation of CD8+ T 
cells thus generating more CTL T cells.  
The ability to produce MHC II de novo is unique to γδ T cells. In addition to 
prompting dendritic cell maturation and producing more MHC II molecules, γδ T cells 
induce the differentiation of CD8+ αβ T cells into alloreactive CTL T cells expanding the 
CTL T cell population 30. Alloreactive CTL T cells are a population of activated highly 
cytotoxic CD8+ T cells that recognize and attack self-antigens, including tumor antigens. 
γδ T cells are able to help naïve CD8+ T cells differentiate into CTL T cells by secreting 
interleukin-2 (IL-2) 30. γδ T cells additionally act as APCs and are capable of 
simultaneously presenting tumor antigens to CD8+ T cells while secreting IL-2 to induce 
their differentiation to CTL T cells 30. γδ T cells thus produce CTL T cells directed 
specifically against tumor cell antigens.  
γδ T cells expand the immune system’s anti tumor response by signaling clusters 
of CD4+ αβ T cells to proliferate and differentiate into Th1 and Th2 cells 30. Wu at el 
observed that another unique ability of γδ T cells, not observed in NK or αβ T cells, was 
their ability, upon licensing, to become phagocytes and serve as professional APCs 36. As 
phagocytes, γδ T cells are able to uptake and process tumor antigens to cross present 
them to tumor specific CD8+ αβ T cells 36.  
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Published Studies 
General Observations-Actions of γδ T cells leading to their investigation as an anti-
tumor immunotherapeutic option 
 
Previous experiments have shown strong reactions of γδ cells with 
Mycobacterium tuberculosis 41, 42 Toxoplasma gondii 43, and Plasmodium falciparum 44. 
More recently, linkage has been shown between Vγ1+ γ: δ T cells and the MHC Class I 
related molecules, MICA and MICB, which are expressed on cells under stress. 
Unexpectedly, a relationship between the NK cell activating receptor NKGD2, expressed 
on the Vγ1+ γδ T cells, and the MICA ligand, led to a strong suspicion that γδ T cells 
might play a significant role in not only stress response, but tumor surveillance as well 45, 
46. γδ T-cells can kill cells effectively through ADCC and the secretion of granzyme A, 
B, perforin, granulysin, Fas ligand, TRAIL, and IFN-γ 47-49. The release of granzyme A 
induces cell death by inflicting damage directly to cells’ mitochondria. Granzyme A 
initiates the release of a large amount of reactive oxygen species and causes the 
mitochondria to lose its transmembrane potential. Granzyme B, on the other hand targets 
caspase 3 either directly or indirectly resulting in the initiation of the caspase cascade and 
DNA fragmentation and apoptosis of the target cell. Perforin is a protein accomplice to 
granzyme A and B and causes cell death by inserting itself into the target cell’s 
membrane. Granulysin initiates cell death by causing an increase in intracellular calcium 
resulting in mitochondrial depolarization, cytochrome c release, caspase activation, and 
eventual apoptosis. Fas and TRAIL are both ligands, which upon binding their 
appropriate receptors induce apoptosis. Table 2 outlines the various roles, as they relate 
to tumor immunology, of the most prevalent cytokines released by γδ T cells.  
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IFN-γ is an extremely important mediator of the immune system’s antitumor 
response. The release of IFN-γ triggers nearby leukocytes in the peripheral blood to 
release several angiostatic chemokines including: IP10, Mig, and I-TAC 50. These 
chemokines, in addition to preventing tumor angiogenesis, attract other effector cells 
from the immune system to the tumor inducing the release of even more IFN-γ 50. Among 
the effector cells recruited are NK cells and macrophages, which release 
imunomodulatory cytokines such as, IL-12 and interleukin-18 (IL-18) 50. As tumor cells 
are killed the antigen presentation machinery of the immune system is primed so that the 
adaptive immune response can be activated to help the innate immune response 50. The 
release of IFN-γ and IL-12 also induces the differentiation of CD4+ T cells into Th1 
antitumor T cells and eventually CD8+ T cells capable of releasing perforin to kill tumor 
cells 50.  
γδ T cells additionally secrete interleukin-13 (IL-13) after encountering 
neuroblastoma cells suggesting that these cells are capable of influencing the activation 
of lymphokine-activated cells (LAK). The population of LAK cells includes NK cells, 
NK T cells, and T cells. The purpose of this population is to enhance both the adaptive 
and innate immune system’s response to tumors. LAK cells inhibit IL-10, an 
immunosuppressant cytokine released by dendritic cells, and secrete large amounts of IL-
8 51. IL-8 is a powerful chemoattractant cytokine, which recruits cells from the immune 
system with either the CXCR1 or CXCR2 receptor to sites of inflammation therefore 
expanding the immune system’s response against tumors 51. LAKs are furthermore able 
to promote dendritic cell maturation while still enabling dendritic cells to acquire 
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molecules, such as tumor antigens, from the external environment 51. The acquisition of 
tumor antigens, released into the external environment from dying tumors, is essential to 
the process of dendritic cell cross priming necessary for CD8+ T cell activation 51. LAKs 
have been associated with both the improvement of dendritic cell CTL T cell priming and 
the reversal of immunosuppressive environments typically surrounding tumors 51.  
Table 2: Most Prevalent Cytokines Released by γδ T cells 
Cytokine Released Action 
Interleukin-1 (IL-1) Inflammation, enhancement of macrophage response, activation of 
endothelial cells resulting in the upregulation of:  
1. ICAM-1/CD54: intercellular adhesion molecule that allows 
activated leukocytes with integrin/LFA-1 on their surface to 
transmigrate into tissues 
2. Vascular cellular adhesion molecule-1 (VCAM-1)/CD106: 
expressed by endothelial cells on blood vessels following cytokine 
release. It is responsible for enabling the adhesion of lymphocytes, 
basophils, monocytes, and eosinophils to vascular endothelium. 
3.   E-selectin/CD62: a cell adhesion molecule expressed on 
endothelial cells upon endothelial cell activation through cytokine 
secretion. E-selectin recruits leukocytes in inflammation and helps 
tumor cells adhere to endothelial cells. The presence of increased E-
selectin is associated with tumor metastases.  
4. ICAM-2/CD102: intercellular adhesion molecule similar in function 
to ICAM-1 ,  
5. IL-8 : chemokine and neutrophil chemotactic factor. Signals 
chemotaxis for neutrophils and other granulocytes while inducing 
phagocytosis and promoting angiogenesis.  
6. Monocyte chemotactic protein-1 (MCP-1)/ CCL2: a cytokine that 
recruits monocytes, memory T cells, and dendritic cells to sites of 
inflammation. 
(see text for more details) 
IL-2 Growth factor for T-cells, promotes differentiation of pCTL, immature 
cytotoxic T lymphocytes unable to perform cytotoxic functions into fully 
functional CTL T cells, enhances NK Cell cytotoxicity 
IL-4 Promotion of differentiation of mature naïve Th0 cells into Th2 cells. Th2 
cells release IL-4, interleukin-5 (IL-5), IL-6, and IL-13. Th2 cells also signal 
to eosinophils, basophils, mast cells, as well as IgE and promote the release 
of histamine. Th2 cells are associated with allergy and inflammation. IL-4 
also stimulated activated B-cells. 
IL-5 Hematopoiesis, chemotaxis, and activation of eosinophils 
IL-6 Promotes the development of Th17 cells and production of C-Reactive 
Protein (CRP). Th17 cells are helper T cells which produce primarily 
interleukin-17 (IL-17) but also: IL-2, interleukin-9 (IL-9), interleukin-22 (IL-
22), GM-CSF, IFN-γ, tumor necrosis factor (TNF) [2#] IL-9 is a cytokine 
responsible for preventing apoptosis and instead stimulating cell 
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proliferation. IL-22 is involved in the innate immune response and a 
powerful mediator of the inflammatory response. Th17 cells are associated 
with tissue inflammation and autoimmune diseases. They are suspected to 
contribute indirectly to antitumor immunity by recruiting T cells, DC cells, 
and trafficking NK cells. Th17 cells have however also been associated with 
supporting the tumor’s microenvironment (2#) 
Interleukin-7 (IL-7) Hematopoiesis, B and T-cell differentiation 
IL-8 Chemotactic for neutrophils 
IL-12 Promote NK cell secretion of IFN-γ 
IL-13 Activation LAK 
Interleukin-15 (IL-15) Recruits NK cells, promotes the proliferation of NK cells, influences NK cell 
development, and activates NK cells. IL-15 signaling also results in the 
upregulation of the NKGD2 receptor, maintenance of the memory T cell 
population, and prevention of apoptosis. In addition to NK cell development, 
IL-15 promotes the development of macrophages and dendritic cells 
IL-17 Release of pro-inflammatory chemokines and cytokines including: IL-6, IL-
8, GM-CSF, granulocyte colony stimulating factor (G-CSF), and 
metalloproteases.  IL-17 is also a chemoattractant for neutrophils. 
Interleukin-33 (IL-33) Activation of mast cells 
MCP-1 Chemotactic for monocytes 
Macrophage inflammatory 
protein-1β (MIP-1β) 
Chemotactic cytokine also referred to as CCL3/ macrophage inflammatory 
protein-1α (MIP-1α form) and CCL4 (MIP-1β form). The release of 
macrophage inflammatory protein (MIP) from monocytes activated by 
bacterial endotoxins results in synthesis and release of pro-inflammatory 
cytokines: IL-1, IL-6, and TNF-α. Secretion of MIP-1β also results in the 
activation of granulocytes.  
G-CSF & GM-CSF Granulocyte and macrophage colony stimulating factor 
IFN-γ Enhances NADPH Oxidase and activates inducible nitric oxide synthase 
(iNOS). The activation of iNOS results in the production of nitric oxide and 
a surge of proinflammatory cytokines including: IL-1, TNFα, and more IFN-
γ. IFN-γ has powerful anti-tumor properties through its signaling to 
angiostatic chemokines, signaling to other immune effector cells, and 
activation of antitumor CD8+ T cells.  
(see text for more details) 
TNF-α Alone, enhances NADPH Oxidase, works synergistically with IL-1 
 
  Neuroblastoma tumor cells do not typically express MHC I molecules and are 
thus particularly susceptible to γδ T cell and NK cell lysis 52-56. The expression of MHC I 
molecules by neuroblastoma tumor cells was shown by Schilbach et al to be induced only 
by exposing neuroblastoma tumor cells to IFN-γ for al least 72 hours 53. Upon the 
upregulation of MHC I molecules, a dose dependent reduction in γδ T cell mediated 
tumor lysis was observed 53. The observed inverse relationship between γδ T cell 
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mediated neuroblastoma tumor cell lysis and MHC I expression is consistent with 
previous published observations and further reinforces existing data suggesting that γδ T 
cells kill neuroblastoma tumor cells in a similar manner as NK cells 53, 57. 
 γδ T-cells, as well as NK cells, can upregulate the immune response against 
tumors through the activation of NKG2D receptors located on their surface 10. Activation 
of the NKG2D receptor triggers the upregulation of CD69 and CD25 by γδ T cells and 
the release of potent cytotoxic granules 10. CD69 and CD25 are both prominent cell 
activation markers. γδ T cells’ NKG2D receptor can be stimulated independently by the 
MICA gene’s protein or the cytokine, IL-15. MICA is a gene responsible for encoding 
the MHC class I chain related gene A. The MHC class I related protein encoded by this 
gene differs from a traditional MHC class I protein in that the MICA protein does not 
associate with beta-2-microglobulin. The MICA protein is known to be a stress induced 
antigen and ligand to NKG2D. Once MICA activates the NKG2D receptor, the NKG2D 
receptor can activate DAP-10, an adaptor protein which complexes with the NKG2D 
receptor in order to activate additional NK and T cells 10. Studies done by Parham et al 
and Rincon-Orozco et al using the RMA mouse tumor cell line provide additional support 
of NKG2D’s recognition of MICA and subsequent signaling and activation of γδ T cells 
8, 10. The activation of γδ T cells through NKG2D signaling is important because it 
enables γδ T cell activation upon NKG2D ligand recognition regardless of antigen 
exposure 10.  
The NKG2D receptor’s downstream signaling pathway can become activated 
once it is primed by IL-15 signaling 58. IL-15 signaling activates Janus Kinase 3 (Jak3), 
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which upon activation phosphorylates a key tyrosine motif within the cytoplasmic tail of 
the transmembrane adaptor protein, DAP10 58. DAP10’s cytoplasmic tail must be 
phosphorylated for signaling to proceed through the NKG2D receptor’s downstream 
signaling pathway 58. Signaling by IL-15 not only primes the NKG2D receptor-signaling 
pathway but also stimulates the upregulation of the NKG2D receptor on the cell surface 
of γδ T cells 8, 10, 58. The discovery that neuroblastoma cells secrete high levels of IL-15 
can be used to more effectively direct cytotoxic γδ cells to tumor cells by trafficking γδ 
cells to those cells producing large amounts of IL-15. This would increase the specificity 
of the immune response thus reducing possible immunopathology. It is important to 
mention as well that IL-15 is vital to NK cell development, maintenance and 
proliferation. A significant finding is that when γδ T cells are cultured with 
neuroblastoma cells a substantial amount of IL-15 is released 33. This suggests that γδ T-
cells could be a beneficial immunotherapeutic agent directly and indirectly through the 
recruitment and proliferation of other immune cells. 
Can γδ T cells be manipulated for immunotherapy? 
 Theoretically γδ T cell based immunotherapy is an attractive therapeutic option 
since γδ T cells are able to directly and indirectly eradicate tumor cells through activating 
a widespread effector response. Furthermore, γδ T cells, unlike CD8+ T cells and NK 
cells, do not rely on MHC presentation or MHC mismatch.  Several obstacles exist 
however, which have impeded the development of γδ T cell based immunotherapies. 
Since γδ T cells comprise only 10% of T cells, the population must first be expanded 48, 
53. The ex vivo expansion of γδ T cells is difficult and often results in a population of cells 
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with a significantly reduced cytotoxicity and half-life 48. Additionally, in the process of 
ex vivo expansion γδ T cells are very susceptible to microbe contamination 48.  In order 
for γδ T cells to become a realistic immunotherapeutic option a means of expanding and 
protecting this population of cells while maintaining their cytotoxicity must be 
discovered.  
 Both Schilbach et al. and Otto et al. have investigated ways of expanding the γδ T 
cell population while maintaining or increasing the population’s cytotoxicity. Otto et al, 
specifically looked at how the half life of γδ T cells could be increased. In his 
experiments Otto et al. used NOD.CB17-Prkdescid/J mice, which he injected (via tail vein) 
with 1x106 neuroblastoma tumor cells from the 1691 tumor cell line 48. The 
neuroblastoma tumor cell injections occurred five to six days prior to five injections, 
spaced one week apart, of 1x106 γδ T cells 58. The γδ T cells used in the injections were 
obtained from human donors and expanded with G-CSF 58. Prior to the injections, the 
cytotoxicity of the γδ T cells was assessed through a europium TDA release assay 58. One 
group of mice received 20µg of hu14.18 four times a week along with the γδ T cells 
while the other group received a IL-7 fusion cytokine (Fc-IL-7 with human IL-7 
sequence) in addition to the 20µg of hu14.18 and γδ T cells once a week 58.  He found 
that γδ T cells when combined with hu14.18 antibody and the IL-7 fusion cytokine had a 
significantly longer half-life 48. Otto et al. proceeded to demonstrate that when the 
combination of γδ T cells, hu14.18, and Fc-IL-7 were infused into mice injected with 
1x106 neuroblastoma tumor cells, the survival time in all of the mice was significantly 
prolonged (p=0.001) 48. These mice had their survival period extended by an additional 
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two weeks (p = 0.005) 48. Addition of Fc-IL-7 was found to be responsible for the 
prolonged survival time (p = 0.04). It is interesting to note that when the mice were 
treated with only the anti-GD2 hu14.18 antibody or Fc-IL-7, their survival period was not 
significantly longer then control mice (p = 0.26) 48.  This observation suggests that IL-7 
alone is not capable of increasing the efficacy of a γδ T cell based immunotherapy even 
though its addition is responsible for the prolonged survival time of mice infected with 
neuroblastoma. It seems paradoxical that the addition of IL-7 to hu14.18 and γδ T cells is 
capable of prolonging the survival period of mice infected with neuroblastoma since it 
has been widely suggested that IL-7 signaling through the IL-7 CD127 receptor may 
promote tumor growth 59. However there are currently no reports of CD127 mRNA 
expression in pediatric tumor cell lines 60. There are also no reports of the IL-7-CD127 
signaling complex in solid tumors 60. IL-7 may therefore be capable of changing its role 
from a tumor growth promoter to a tumor growth inhibitor pending the presence of 
CD127. The in vivo results observed by Otto et al. using mice infected with 
neuroblastoma were also observed in vitro when the group repeated their experiment on 
the NB1691 neuroblastoma cell line 48.  
Schilbach et al collected peripheral blood mononuclear cells (PBMC) from 
patients and treated them with Orthoclone OKT3 (OKT3) 53. OKT3 is an 
immunosuppressant drug used to reverse acute graft rejection. It inhibits T-cell function 
by blocking CD3 thus affecting early T-cell activation and cytokine release among other 
T-cell functions. Schilbach et al found that 12 days post OKT3 treatment the prevalence 
of γδ T cells in PBMC increased from 7.6% (SD 4.2%) to 16.5% (SD 9.9%) 53. On day 
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22 of culture, 98.9% of PBMC were γδ T-cells and of these 65.9% (SD20.9%) co 
expressed the NK cell marker, CD56 53. Through his experiments Schilbach et al 
demonstrates that the proportion of γδ T cells in PBMC steadily increases when αβ T 
cells are inactivated. Although it remains unknown why the γδ T cell population expands 
upon αβ T cell inactivation it is reasonable to suggest that the observed expansion in γδ T 
cells serves a compensatory mechanism. If the process of in vivo αβ T cell inactivation 
through OKT3 exposure resulting in the compensatory increase in the γδ T cell 
population can be recreated ex vivo, it may serve as a possible way of expanding the γδ T 
cell population ex vivo.  
Following γδ T cell expansion, Schilbach et al. proceeded to demonstrate the 
effect that γδ T cell prevalence has on γδ T cell cytotoxicity. Schilbach et al. incubated 
the LS neuroblastoma cell line with human γδ T-cells obtained from healthy donors at 
effector: target ratios ranging from 0.3: 1 to 20: 1 and used a BATDA release assay to 
asses the γδ T cell’s cytotoxicity 53. A BATDA release assay measures the degree of cell 
lysis by measuring the intensity and scope of a fluorescent signal produced when the 
hydrophobic intracellular ligand, TDA combines with an extracellular Eu-solution. The 
TDA ligand is formed inside the cell upon hydrolysis of an ester bond present in the 
initial cell loading solution, acetooxymethyl (aceto) ester of fluorescence enhancing 
ligand. The hydrophobic ligand, TDA, formed following ester cleavage cannot cross the 
cell membrane and thus its exit from the cell and combination with Eu-solution to 
produce a fluorescent signal indicate cell lysis. Using a BATDA release assay, Schilbach 
et al observed that γδ T cells maintained their cytotoxic function at an effector: target 
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ratio of 20:1 however when the effector: target ratio was reduced to 1.25:1 only 18% 
showed medium cytotoxicity and 73.8% showed low cytotoxicity 53. Medium 
cytotoxicity was defined as specific target cell lysis greater then 30% but less then 50% at 
an effector: target ratio of 20:1 while low cytotoxicity was defined as specific target cell 
lysis less then 30% at an effector: target ratio of 20:1 53. When the group of γδ T-cells at 
an effector: target ratio of 20:1 showing low cytotoxicity was stimulated with IL-2 for 24 
hours, the mean cytotoxicity rose to 81% 53. Otto et al also observed that when γδ T cells 
were stimulated with IL-2 68% of the γδ T cells remained viable and maintained their 
cytotoxicity for more then 10 days in culture 48.  
Schilbach et al additionally observed that all γδ T-cells showed high spontaneous 
killing at an effector: target ratio of 20:1 regardless of whether they were stimulated with 
IL-2 53. When γδ T-cells that had been stimulated with IL-2 for 24 hours were incubated 
with 6 neuroblastoma cell lines: LS, IMR 5, IMR 32, SK-N-LO, SK-N-SH, and Kelly at 
effector: target ratios ranging from 10:1 to 0.6:1 a sustained 30 day high degree of 
cytotoxicity against neuroblastoma cells was observed 53.Schilbach et al. demonstrates 
the necessity of expanding the γδ T cell population to maintain cytotoxicity. His work 
also supports the use of IL-2 during the process of ex vivo expansion. 
Activation and Expansion of γδ T cells through Phosphonates and Phosphorylated 
Structures 
 
 Observations by Schilbach et al. suggest that γδ T cells target and kill 
neuroblastoma tumors by binding to phosphorylated structures presented on the surface 
of neuroblastoma tumor cells 53. When both the neuroblastoma cell line, LS and 
neuroblastoma tumor cells were treated with acid phosphatase and then incubated with γδ 
  33 
T cells, 78% of the plates containing acid phosphatase treated neuroblastoma tumor cells 
exhibited a significant reduction in tumor cell lysis compared to plates with untreated 
neuroblastoma tumor cells 53. Since acid phosphatase treatment is expected to release 
phosphate structures from the surface of neuroblastoma tumor cells, Schilbach et al’s 
observations suggest that binding of γδ T cells to phosphorylated structures on 
neuroblastoma tumor cells is a key aspect of neuroblastoma cell lysis 53.  
In addition to investigating how γδ T cells are able to recognize and bind to 
neuroblastoma tumor cells, cancer immunologists have focused on learning the 
mechanism behind γδ T cell stimulation and expansion upon neuroblastoma tumor cell 
recognition. This is of particular interest to cancer immunologists because until recently, 
the low prevalence of γδ T cells has been a significant barrier preventing the use of γδ T 
cells in immunotherapy. Recently it has been widely observed that γδ T-cells can be 
stimulated and made highly cytotoxic through treatment with phosphonates such as 
isopentenyl diphosphate (IPP) 10, 53, 57, 61-65. Unfortunately many phosphonates are toxic 
which limits the immunotherapeutic use of γδ T cells. As an alternative to the powerful 
yet cytotoxic phosphonates such as IPP, Schilbach et al investigated the effects of 
Clondronate, a less toxic phosphonate, currently used to treat hyperkalemia, on γδ T cells 
53. Treatment of γδ T cells with Clondronate and IL-2 resulted in a significant increase in 
cytotoxicity against neuroblastoma tumor cells at effector: target ratios ranging from 20:1 
to 1.2:1 53. The cytotoxic potential of γδ T-cells treated with Clondronate and IL-2 was 
17% higher than controls treated with IL-2 alone even at the lowest effector: target ratios 
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53. Furthermore, Clondronate was able to increase the proliferation of γδ T cells 35.8 to 
57.8 times higher 53. 
Another phosphonate studied for its ability to stimulate γδ T cell proliferation is 
Bromohydrin Pyrophosphate (BrHPP). Chargui et al. examined BrHPP’s ability to 
expand γδ T cells and induce the secretion of IFN-γ and TNF from γδ T-cells using 
PBMC from 10 patients with neuroblastoma at varying stages of disease (6 immediately 
after diagnosis prior to all treatment, 9 following induction therapy, and 4 following 
autologous transplant) 57. γδ T cells from PBMC of patients immediately following 
diagnosis proved to be the most susceptible to BrHPP 57. γδ T cells from these patients 
showed a 127.63% expansion 57. γδ T-cells from PBMC of patients following autologous 
stem cell transplant showed an 82.03% expansion 57. This data supports the use of BrHPP 
for the ex vivo expansion of γδ T cells. It was further shown that in 69% of the PBMC 
samples the prevalence of γδ T cells in the samples increased from 26.07% to 89% 
following a 14-day treatment with BrHPP 57. Following 8 days of BrHPP stimulation, 
samples from neuroblastoma patients were composed of 70% CD3 γδ T cells and less 
then 2% αβ CD3 T cells 57. It was also observed that 63% of the γδ T cells in the samples 
showed a rapid increase in CD25, by day 7 57. CD25 is the alpha chain of the IL-2 
receptor and signifies γδ T cell activity. 
 γδ T-cells stimulated with BrHPP consistently express CD69, a signal transmitting 
receptor on lymphocytes that plays an important role in lymphocyte proliferation 57.   γδ 
T cells also expressed the NK cell markers CD56, CD158, and NKGD2. When γδ T cells 
from patients with neuroblastoma were cultured overnight with BrHPP, they were able to 
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kill 80% of neuroblastoma tumor cells at an effector: target ratio of 30:1 57. Antibody 
blocking studies on γδ T cells stimulated by BrHPP suggest that γδ T cells interact and 
kill neuroblastoma tumor cells through their NKGD2 receptor 57.  
 One significant finding of Chargui et al. was that γδ T cells are capable of killing 
neuroblastoma tumor cells without the anti-GD2 antibody and solely through BrHPP 
activation 57. The stimulation of γδ T with BrHPP shows promise as a means of 
expanding and furthermore activating γδ T cells ex vivo to be used for autologous 
transplantation 57.  
 Zoledronic acid is another phosphoantigen that has proven to be a powerful 
activator of γδ T cells. Three important populations of γδ T cells are the CD45+ CD27+, 
and CD45- CD27+ memory cells and the CD45- CD27- IFN-γ producing cytotoxic cells 61, 
62. The CD45 marker is also known as the common leukocyte antigen and is a protein 
tyrosine phosphatase responsible for dephosphorylating phosphotyrosine residues. The 
CD27 marker is a TNF receptor essential for both the generation and maintenance of T 
cell immunity, B cell activation, and subsequent immunoglobulin formation. The 
prevalence of these specific populations within the peripheral circulating γδ T cell 
population is one way of monitoring γδ tumor surveillance and anti-tumor immune 
initiation since these populations signify presence and activity γδ T cells carrying out an 
anti-tumor immune attack 62. Dieli et al. observed that the prevalence of CD45+ CD27+, 
CD45- CD27+, and CD45- CD27- as well as the production of IFN-γ by Vγ1 γδ T cells 
following in vitro stimulation with IPP consistently increased upon zoledronic acid 
treatment 62. Dieli et al’s observations correspond with other evidence demonstrating that 
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γδ T-cells can be effectively isolated from patients through leukophoresis, expanded and 
stimulated using zoledronic acid or other phosphonates and then infused back into 
patients to produce a powerful anti-tumor immune response 63. Pechhold et al. and other 
laboratories have demonstrated that phosphonates can be directly infused into patients to 
produce a potent anti-tumor response 66. The direct infusion of phosphonates and ex vivo 
phosphonate stimulation of γδ T cells both require the concurrent administration of IL-2 
66. The use of zoledronic acid and phosphonates to stimulate a γδ T cell mediated anti-
tumor immune response in multiple myeloma and non-Hodgkin’s lymphoma has also 
been studied. Wilhelm et al. found that 33% of his patient population with either multiple 
myeloma or non-Hodgkin’s lymphoma showed partial tumor remission and a 
corresponding significant increase in the prevalence of activated γ: δ T cells following 
zoledronic acid infusion 67, 68.  
 Currently (E)-4-Hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) has 
proven to be the most potent phosphoantigen capable of activating γδ T cells 69- 72. HMB-
PP is an intermediate of the non-mevalonate pathway used to produce dimethylallyl 
pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP), which are necessary for 
cell membrane synthesis and maintenance, hormone synthesis, N-glycosylation, and 
protein anchoring. Dunne et al, among others, have observed that if   γδ T-cells, treated 
with HMB-PP, are incubated with immature dendritic cells, the dendritic cells mature and 
upregulate crucial co-stimulatory adhesion molecules including: HLA-DR, CD11c, 
CD54, CD40, CD83, CD86 and CCR7 69. The upregulation of these surface markers on 
dendritic cells typically occurs following dendritic cell treatment with agents such as, 
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polyinosinic: polycytidylic acid (poly I: C) 69. Poly I: C, along with other similar agents, 
induces cytotoxic activities in cells with which they interact 69. The upregulation of these 
co-stimulatory adhesion molecules by dendritic cells following γδ T cell exposure further 
supports the claim that γδ T-cells have a high cytotoxic potential 69. In addition to 
dendritic cell upregulation of key co-stimulatory molecules signifying their maturation 
and activation following exposure to HMB-PP treated γδ T cells express a similar highly 
cytotoxic phenotype consisting of the cell activation markers: CD25, CD69, and CD56 59, 
69. Dunne et al and others, have also demonstrated that γδ T cells are able to function as 
APCs by showing that γδ T cells express HLA-DR and the co stimulatory molecule 
CD86 following HMB-PP exposure 69, 72- 74.  
Selection of the Vγ1 γδ T Cell Phenotype for Immunotherapy 
Schilbach et al. observed that when γδ T cells were exposed to neuroblastoma 
tumor cells the collection of cytokines secreted by the Vγ1 γδ T cell phenotype differed 
from those secreted by the Vγ2 γδ phenotype 49. The collection of cytokines secreted by 
Vγ2 γδ T cells includes angiogenin, vascular endothelial growth factor (VEGF), 
epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1), all of which 
support tumor growth and angiogenesis 49. Vγ1 γδ T cells on the other hand immediately 
stop secreting angiogenin, VEGF, EGF, IGF-1, platelet derived growth factor (PDGF), 
and growth regulated oncogene (GRO) upon exposure to neuroblastoma cells 49. GRO 
belongs to the CXCL1 family of chemokines and supports malignant tumor growth, 
invasive tumor behavior, and is a powerful inflammatory cytokine with growth regulation 
properties 49. Instead of secreting cytokines supporting tumor growth and angiogenesis, 
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Vγ1 γδ T cells secreted pro-inflammatory cytokines that proved to be significantly more 
cytotoxic against neuroblastoma tumor cells then those secreted by Vγ2 γδ T cells 49. 
Additionally the microenvironment created by Vγ1 γδ cells was more toxic to 
neuroblastoma tumor cells then that created by Vγ2 γδ T cells 49.  
Typically peripheral circulating Vγ2 and Vγ1 γδ T cells are present in a ratio of 
5:1 (Vγ2: Vγ1) 49. In a 5:1 ratio (Vγ2: Vγ1) a γδ T cell mediated anti tumor response 
cannot be observed since the majority of tumor activated γδ T cells, at this ratio, secrete 
cytokines, which support tumor growth and angiogenesis. However when γδ T cells are 
treated with Pamidronate, a phosphonate, the ratio of Vγ2: Vγ1 γδ T cells shifts from 5:1 
to 1:11 suggesting that phosphoantigens are capable of serving as potent activators of the 
most effective γδ T cell phenotype able to illicit an immune response against tumors 49.  
Schilbach et al. also observed that when neuroblastoma tumor cells were 
incubated with Vγ1 γδ T cells the Vγ1 cells continued to secrete high levels of IL-2 and 
CCL1 75.  IL-2 is a powerful cytokine necessary for the activation and proliferation of 
effector T cells as well as the generation of immunological memory. CCL1 acts as a 
powerful chemo attractant for monocytes. Additionally, a 3.2 and 1.5 fold increase in the 
release of TNF-α and monocyte chemotactic factor-2 (MCP-2) and an 8.1 fold 
upregulation of MCP-1 was observed when Vγ1 γδ T cells were exposed to 
neuroblastoma cells. MCP-1 and MCP-2 are both powerful chemo attractant molecules 
for monocytes. Specifically, MCP-1 recruits monocytes, memory T cells, and dendritic 
cells to sites of inflammation or infection while MCP-2 is capable of binding chemokine 
receptors to activate cells of the immune system. An increase in MCP-1 and/or MCP-2 is 
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beneficial because it promotes a more robust immune response. The significant increase 
in IL-2, CCL1, TNF-α, MCP-1 and MCP-2 following Vγ1 γδ T cell exposure to 
neuroblastoma tumor cells provides further evidence that the Vγ1 γδ phenotype can also 
indirectly exert cytotoxic effects against neuroblastoma cells by signaling to other 
immune effector cells.  Vγ1 γδ T cells also secreted significant amounts of IL-4 upon 
exposure to neuroblastoma tumor cells 49. IL-4 is a cytokine that induces the 
differentiation of naïve Th0 cells to Th2 T cells and assists with B cell activation. 
Inconsistencies in NK Cell Mediated Immunotherapy 
While NK cells and monoclonal anti-GD2 antibodies can be activated or designed 
to target specific tumor cells, they act alone, recruit a transient natural immune response, 
and in the past have not been as effective on solid tumors such as neuroblastoma 76, 77. 
Additionally NK-mediated lysis and neuroblastoma tumor cell susceptibility is prone to 
environmental and genetic influences making it a less reliable treatment option. Many 
current studies, such as one performed by Delgado et al. in collaboration with the COG, 
have tried to demonstrate success using NK cell mediated immunotherapy based on the 
NK cell’s ability to elicit a powerful graft vs. tumor response.  The graft vs. tumor 
response elicited by NK cells is rooted in the high degree of polymorphism of the KIR 
inhibiting receptors, which results in a high incidence of mismatched KIR receptor pairs 
28, 57. The high degree of reactivity observed between NK cells with mismatched 
inhibiting KIR receptor pairs is the foundation of the “missing self” hypothesis used to 
describe NK cell’s immunotherapeutic potential. Ruggeri et al. has demonstrated that 
donor licensed NK cells, infused into a recipient lacking at lease one MHC I ligand for 
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the donor’s inhibiting KIR receptors, lead to a lowered NK cell activation threshold 
which resulted in a more potent immune response 11. Ruggeri et al. proved that the 
recipient’s enhanced effector response and increased tumor clearance was due to the 
infusion of alloreactive NK cells with mismatched inhibiting KIR receptors pairs. He 
isolated the alloreactive NK cells for three months following HSCT and blocked the 
immune response initially observed in the recipient by incubating the NK cells with 
target T cells that expressed matching inhibiting KIR receptor ligands 11.  
The study conducted by Delgado et al. involved 39 patients with neuroblastoma, 
ranging in age from 1 year to 21 years of age 24. Delgado et al. separated the patients into 
two strata depending on their disease status as measured through standard imaging and 
clinical evaluation at the start of the study 24. Stratum one contained 15 patients with 
disease measurable by standard radiological techniques whereas stratum two consisted of 
24 patients whose disease could only be measured by MIBG scintigraphy 24. MIBG 
scintigraphy uses a radiolabeled molecule, MIBG, which closely resembles noradrenaline 
and as such localizes within adrenal tissue. The detection of disease through MIBG 
scintigraphy but not standard radiological techniques indicates non-bulky disease 
confined to adrenal tissue. Delgado et al. received 38 DNA samples from the 39 
participants and determined the KIR/KIR ligand genotype of participants 24. The seven 
participants that showed either a complete response (defined as disease free survival 
lasting longer then 35 months) or stable disease (disease present yet marked clinical 
improvements and clearing of disease from all marrow) following infusion of the anti-
GD2 hu14.18 antibody and IL-2 all had a mismatched KIR/KIR ligand genotype 24. None 
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of the study participants with a matched KIR/KIR ligand genotype showed complete 
recovery 24. Instead, 12 of the 14 participants found to have a matched KIR/KIR ligand 
genotype exhibited progressive disease 24. Although a statistically significant correlation 
(p=0.03) between a mismatched KIR/KIR ligand genotype and hu14.18 treatment 
response was found, it is important to note that 75% of study participants with a 
mismatched KIR/KIR ligand genotype were placed in stratum two and therefore were 
found to have non-bulky neuroblastoma locally confined to the adrenal gland at the start 
of the study 24. Furthermore the correlation between disease status with and without 
hu14.18 immunotherapy, assessed by the stratum each patient was placed into at the start 
and conclusion of the study, and KIR/KIR ligand genotype was not found to be 
statistically significant (p=0.08) 24. Therefore, although Delgado et al.’s results suggest 
that patients with a mismatched KIR/KIR ligand genotype will respond favorably to 
hu14.18 treatment attaining either complete recovery or stable disease with signs of 
clinical improvement, it cannot be concluded that all patients with a mismatched 
genotype, regardless of initial disease status, will manifest a less established disease 
following treatment with hu14.18 24. 
 The presence of danger signals, ligands expressed by healthy cells but 
overexpressed by tumor cells, activates NK cells through activating receptors located on 
the NK cell’s surface 29. In addition to the NKG2D receptor, NK cells also express the 
NKp46, NKp44, and NKp30 activating receptors 29. Aside from the mixed lineage 
leukemia protein (MLL5) and B7-H6, many of the danger antigens, which bind and 
activate the NK cell’s activating receptors, remain unknown 29. In order for NK cells to 
  42 
become fully active and orchestrate an attack, NK cells’ activating receptors must either 
be solely engaged or overwhelmingly engaged with complementary activating ligands 29. 
If both activating and inhibiting receptors are engaged, the NK cell will be inhibited 29. 
Therefore tumor cells which express MHC I molecules typically evade attack by NK 
cells since the MHC I molecules serve as ligands to NK cell’s inhibiting KIR receptors. 
Neuroblastoma tumor cells in general do not express high levels of MHC I molecules and 
are thus susceptible to NK cell mediated lysis. Raffaghello et al however observed that 
when neuroblasts isolated from patients with stage 4 neuroblastoma were treated with 
activated allogenic NK cells, increased IFN-γ concentrations resulted in increased 
expression levels of MHC I molecules on the neuroblasts 78. The increased expression of 
MHC I molecules lowered neuroblasts’ susceptibility to NK cell mediated lysis 78. 
Raffaghello et al.’s observations correlate with observations by Lorenzi et al who 
reported that both IFN-γ and TNF-α, secreted by NK cells, activates the transcription of 
MHC I molecules 79. Although IFN-γ and TNF-α are also secreted by γδ T cells, their 
presence does not impinge on γδ T cell’s ability to lyse tumor cells because γδ T cells are 
not affected by the presence of MHC I or MHC II molecules. An increase in MHC I 
expression and consequential decrease in NK cell mediated tumor lysis was also observed 
by Neal et al in mice treated with anti-GD2 monoclonal antibodies that engage the FcγR 
on tumor cells 80. The increase in MHC I expression observed in anti-GD2 antibody 
treatment results from increased secretion of IFN-γ following the engagement between 
the anti-GD2 antibody and FcγR on neuroblastoma tumor cells 80.  
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 Additional factors such as the presence or absence of CD155 and the poliovirus 
receptor on neuroblastoma tumor cells have proven to effect tumor cell susceptibility to 
NK cell mediated lysis. CD155 interacts with the DNAM-1 receptor on NK cells and 
signals DNAM-1 receptor activation of NK cell’s NKG2D receptor 29. In studies using 
bone marrow aspirated neuroblasts from patients with neuroblastoma it has been 
observed that an increased presence of CD155 on neuroblasts increased the neuroblast’s 
susceptibility to NK cell mediated lysis 29. Neuroblasts from bone aspirates of patients 
with metastatic disease have shown either limited or absent expression of CD155 29. 
These observations all suggest that the expression of CD155 on neuroblastoma tumor 
cells may be important for optimal NK cell-mediated tumor lysis. The status of CD155 
expression on neuroblastoma tumor cells could thus limit the effectiveness of NK cell 
based immunotherapy in some neuroblastoma patients.  
 Neuroblastoma tumor cells are capable of evading NK cell mediated attack 
through a variety of mechanisms. Just as the expression status of CD155 on 
neuroblastoma tumor cells could limit the ability of NK cells to kill tumor cells, the 
absence of CD155 ligands on NK cells could impede NK cell mediated tumor lysis 29. 
Neuroblastoma cells also tend to release substantial amounts of soluble MICA protein, 
which decreased NK cell activation 29. NK cell activity is further dampened by the 
release of tumor growth factor-β (TGF-β) by neuroblastoma tumor cells which 
downregulates the expression of the activating NKp30 and NKG2D receptors on NK 
cell’s surface 29. Although the levels of TGF-β secreted by neuroblastoma tumor cells are 
not significant enough to have a drastic impact on the presence of NKG2D receptors on 
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the NK cell surface, they are significant enough to significantly impact NK cell’s 
expression levels of various chemokine receptors 29. The chemokine receptors expressed 
by NK cells influence NK cell interactions with the endothelium, their recruitment into 
peripheral tissues, and their movement from the bone marrow 29. Therefore through 
influencing the chemokine receptor expression profile of NK cells, TGF-β, secreted by 
neuroblastoma tumor cells, can significantly impact NK cell mediated tumor lysis.  
 Another factor that could possibly limit the therapeutic value of NK cells is their 
potential dependence on the invariant chain NK cell (iNK) population to exert their 
cytotoxic effects 81- 83. iNK cells differ from NK cells in that they express a monospecific 
TCR capable of recognizing foreign and self glycerol or ceramide based lipid antigens 
presented by the CD1d cell marker 84. The activity of iNK cells is thus not controlled by 
KIRs, lectin-like receptors, or natural cytotoxicity receptors (NKp30, NKp44, and 
NKp46) 84. iNK cells also differ from NK cells in that they undergo somatic 
recombination and selection in the thymus and thus share some developmental traits with 
cells of the adaptive immune system 84. Although their development in the thymus 
resembles the development or other cells in the adaptive immune system, iNK cells 
respond in an innate manner by secreting danger signals and proinflammatory cytokines 
within hours of activation 84. iNK cells are referred to as preconditioned effector cells due 
to their unparalleled rapid production and secretion of cytokines upon activation 84. 
Because iNK cells are not defined by a single group of markers they are commonly 
divided into subsets by cell surface markers and behavior resembling other more defined 
populations of immune cells 84. Although iNK cells make up only 0.1%-0.2% of T cells 
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in the peripheral blood, they compose 10% of T cells in the gastrointestinal momentum, 
the origin of many neuroblastoma tumors 84.  
 A study conducted by Saito et al. demonstrated that when the iNK cell population 
was knocked out of mice, a significantly lower amount of NK cells and dendritic cells 
were able to become activated and exert a cytotoxic attack against tumor cells 81. Saito et 
al’s study suggests that NK cells are not capable of eliciting an anti-tumor immune 
response on their own but instead require the presence of another sub-population of NK 
cells. The reliance of NK cells on the iNK population would be an additional factor to 
consider when using NK cell based immunotherapy 81. In addition to NK cell dependence 
on MHC I and CD155 expression status.  
Clinical Trials investigating γδ T cell based immunotherapy and the proposed 
advantages and disadvantages of γδ T cell immunotherapy 
 
Clinical trials investigating the effectiveness of γδ T cell based immunotherapy in the 
treatment of neuroblastoma are limited. Currently Dr. Joseph Pressey is conducting a 
pilot study at the University of Alabama School of Medicine investigating the efficacy of 
zoledronic acid and IL-2 treatment to elicit a γδ T cell response in patients with 
neuroblastoma 85. Initial results from Dr. Pressey’s investigation have not yet been 
released. Although the clinical trials on γδ T cell based immunotherapies for 
neuroblastoma are limited, there have been several clinical trials involving γδ T cell 
based immunotherapy for other types of cancer, most notably renal cell carcinoma, lung 
cancer, breast cancer and lymphoid malignancies 57, 64, 68, 86- 89. These studies showed 
significant tumor regression when γδ T cells were expanded ex vivo with 
phosphoantigens and adoptively transferred into patients. The studies completed on 
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patients with lung, breast, and renal cell carcinoma were particularly promising because 
the adoptive transfer of the ex vivo expanded γδ T cells had a significant impact on these 
tumors which in the past have not shown a dramatic response to immunotherapy 86- 88. 
 Although bench and clinical research examining the effectiveness of γδ T cell 
based immunotherapy for neuroblastoma and other cancers has shown promise there are 
several potential barriers, which must first be overcome. In order for γδ T cells to exert a 
significant anti-tumor immune response they must be expanded ex vivo. The injection of 
an extremely large amount of ex vivo expanded γδ T cells can induce the secretion of 
numerous inflammatory cytokines causing deleterious side effects 16. Additionally, 
although TGF-β does not suppress the activity of γδ T cells through the same mechanism 
it uses to suppress NK cell activity it promotes the activity of Th17 cells and the 
upregulation of regulatory T cells 47, 90, 91. Tumor cells secrete TGF-β in order to escape 
immunosurveillance. In addition to offering support to Th17 cells and regulatory T cells, 
TGF-β upregulates a subpopulation of γδ T cells that express the Foxp3+ phenotype and 
have immunosuppressant abilities 47, 90, 91. It is important to note however that the 
upregulation of Foxp3+ γδ T cells by TGF-β has only been observed in the mouse and not 
in humans. Given the complexity of the immune system it cannot be concluded with a 
high degree of certainty that the molecules secreted by tumor cells and the immune 
system’s response to these molecules in mice mirrors the response in humans.   
 γδ T cells exhibit several distinct advantages making them attractive candidate 
cells for immune based therapies. One of the most significant advantages of γδ T cell 
based immunotherapy is the ability of γδ T cells to exert a potent anti-tumor immune 
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response by both directly killing tumor cells and by promoting the maturation, 
recruitment, and proliferation of other immune cells, specifically dendritic and NK cells, 
through IL-15 signaling 31, 33, 47, 49, 53, 57, 69, 72 -75 92, 93- 96. γδ T cells additionally secrete IL-
12 and Th1 cytokines, which induce the maturation of immature dendritic cells to mature 
APC 72. By maintaining the balance of Th1/Th2/ and Th17 cytokines, γδ T cells have an 
even greater control of the strength and nature of the immune system’s anti-tumor 
response.  
 Immunotherapies that employ γδ T cells are preferable to those using NK cells 
because γδ T cell activation and attack does not depend on the status of MHC I 
molecules, or other activators such as CD155 on the tumor cell’s surface. Since γδ T cells 
act independently of MHC I molecules, their activation and attack potency is not 
hindered by increased levels of IFN-γ as is the case with NK cells 97. Both NK cells and 
γδ T cells can be activated through the NKG2D activating receptor expressed on their cell 
surface. The secretion of soluble MICA protein and TGF-β however can block NKG2D 
receptor activation. Furthermore, the absence of danger signals such as CD155 or the 
DNAM receptor can block NKG2D receptor activation. If activation of the NKG2D 
activating receptor is blocked then NK cells will not be able to elicit an anti-tumor 
immune response. γδ T cell activation and initiation of a powerful anti-tumor immune 
response does not depend solely on the NKG2D receptor 44, 61, 98. Non-peptide 
phosphoantigens and aminobisphosphate drugs such as zoledronic acid can instead 
activate γδ T cells 44, 61, 98. Therefore tumor antigen expression profiles that inactivate NK 
cells do not affect γδ T cells.  
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 Several other important qualities of γδ T cells making them ideal candidates for 
immunotherapy include the simultaneous secretion of proinflammatory cytokines, pro 
apoptotic molecules, and ability to carry out cell-cell contact lysis, as well as their ability 
to present tumor antigens to both CD4 and CD8 T cells 97, 99.  
Conclusion 
Table 3 outlines both the advantages and disadvantages of using either NK cell 
mediated or γδ T cell mediated immunotherapy to treat neuroblastoma.  
Table 3: The Advantages and Disadvantages of NK cell and γδ T cell 
Immunotherapy 
 
Immunotherapy Cell Advantage Disadvantage 
NK Cell -Doesn’t require previous MHC 
mediated antigen presentation  
-Secretes numerous cytotoxic 
cytokines: TNF-α, granzyme B, 
perforin, IL-22, CCL3, CCL4, IL-
8, IFN-γ 
-The high degree of 
polymorphism in NK cell’s KIR 
receptors increase the probability 
of mismatched KIR/KIR receptor 
pairs enabling NK cells to carry 
through a powerful tumor vs. 
graft response. 
-NK cell activation requires either 
the absence of MHC expression 
or MHC/KIR mismatch 
-Inability to produced memory 
cells making the immune 
response more transient which 
could increase the risk of relapsed 
disease 
-Possible reliance on the iNK cell 
population to achieve full 
cytotoxicity 
-NK cell cytotoxicity against 
tumor cells can be dampened by 
monoclonal antibody treatment 
-NK cell immunotherapy is not 
ideal for solid tumors 
-NK cell activating receptors 
must be solely or overwhelmingly 
engaged to their complementary 
ligands on tumor cell surface or 
the NK cell will be inhibited 
-The high degree of IFN-γ and 
TNF-α secreted by NK cells 
upregulates MHC I expression 
which in turn downregulates 
tumor cell’s susceptibility to NK 
cell mediated lysis 
-NK cell activation status is 
heavily affected by the presence 
or absence of danger signals such 
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as CD155 expressed on tumor 
surface 
-NK cells release soluble MICA 
which decreases NK cell 
activation 
-The release of TGF-β by 
neuroblastoma cells causes NK 
cells to downregulate the 
activating receptors NKp30 and 
NKG2D 
γδ T cell -γδ T cell activation does not 
depend on the absence, presence, 
or mismatch of MHC 
-Since γδ T cell activation is 
MHC independent, activation and 
cytotoxicity is not affected by 
increased levels of IFN-γ, TNF-α 
-Ability to acquire characteristics 
of professional APC 
-Expression of CCR7 enabling αβ 
T cell antigen presentation 
-Expression of TLR and the 
ability to activate TLR enabling 
γδ T cells to recognize DAMPS 
expressed on the surface of tumor 
cells 
-γδ T cells promote the 
maturation of DC cells 
-γδ T cells can produce MHC II 
de novo and upregulate MHC II 
expression 
-The ability to induce the 
differentiation of CD8+ αβ T cells 
into CTL cells 
-γδ T cells signal for the 
proliferation and differentiation 
of Th1 and Th2 cells as well as 
control Th1/Th2/Th17 cytokine 
balance 
-Ability to become phagocytes 
that cross present tumor antigens 
to CD8+ and CD4+ αβ T cells 
-γδ T cells secrete numerous 
potent cytokines: IL1, IL2, IL4, 
IL5, IL7, IL8, IL12, IL13, IL33, 
MCP1, CCL1 and Th1 cytokines 
which kill tumor cells directly 
and recruit as well as activate 
other powerful effector cells for 
an expanded immune response. 
-γδ T cells secrete IL-15 which is 
responsible for NK cell 
differentiation, maturation, 
-Due to the low prevalence of γδ 
T cells, they must undergo ex 
vivo expansion. The ex vivo 
expansion of γδ T cells has been 
associated with decreased γδ T 
cell cytotoxicity and half life and 
an increased risk of microbial 
contamination 
-Risk of cytokine storm following 
the infusion of an expanded γδ T 
cell population 
-γδ T cells promote Th17 cell 
activity and upregulate regulatory 
T cells 
-In mice, TGF-β secreted by 
neuroblastoma cells upregulates 
the Foxp3+ phenotype of γδ T 
cells  
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proliferation, and maintenance 
-γδ T cell can be activated 
through multiple mechanisms 
including NKG2D receptor and 
phosphoantigens 
 
In the past, γδ T-cells have not been considered a viable therapeutic option due to 
difficulties in maintaining γδ T cell cytotoxicity following ex vivo expansion. This 
challenge has been overcome through the use of phosphoantigens with concomitant 
administration of IL-2 63, 66- 68. The primary advantage in using γδ T cell mediated 
immunotherapy rests in the ability to activate γδ T cells through multiple non-MHC 
dependent mechanisms and generate a wide immune response involving APCs such as 
dendritic cells, NK cells, CD8+ and CD4+ αβ T cells, and LAK cells 69, 73, 74, 94-96. The 
findings of this thesis suggest that γδ T cells have the potential to become a highly 
effective immunotherapeutic agent for the treatment of neuroblastoma.  
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